TAVR for patients with low risk for mortality is here for investigation
In November 2015, the US Food and Drug Administration (FDA) granted the first Investigational Device Exemption (IDE) to evaluate the safety and effectiveness of transcatheter aortic valve replacement (TAVR) in…